Cargando…

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

INTRODUCTION: Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phase IIb trials investigated the long-term safety and effectiveness of peficitinib. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genovese, Mark C., Greenwald, Maria W., Gutierrez-Ureña, Sergio R., Cardiel, Mario H., Poiley, Jeffrey E., Zubrzycka-Sienkiewicz, Anna, Codding, Christine E., Wang, Annie, He, Weizhong, Amos, Rebecca, Vinueza, Raul, Wang, Xuegong, Garg, Jay P., Kivitz, Alan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858430/ https://www.ncbi.nlm.nih.gov/pubmed/31410787 http://dx.doi.org/10.1007/s40744-019-00167-6

Ejemplares similares

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
por: Diller, Magnus, et al.
Publicado: (2019)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2021)

Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis
por: Nishimura, Akito, et al.
Publicado: (2022)

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
por: Ikari, Yuzo, et al.
Publicado: (2019)

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
por: Zhu, Tong, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
por: Gao, Xin, et al.
Publicado: (2022)

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
por: Kitanaga, Yukihiro, et al.
Publicado: (2020)

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction
por: Oba, Yuki, et al.
Publicado: (2022)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Phosphate reabsorption in the kidney: NaPi-IIb or not IIb
por: Burns, David, et al.
Publicado: (2020)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

IIb or not IIb? Regulation of myosin heavy chain gene expression in mice and men
por: Harrison, Brooke C, et al.
Publicado: (2011)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Genovese, Mark C., et al.
Publicado: (2016)

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
por: Genovese, Mark C, et al.
Publicado: (2014)

Type IIB Orientifolds without Untwisted Tadpoles, and non-BPS D-branes
por: Rabadan, Raul, et al.
Publicado: (2000)

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2019)

The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial
por: Dakin, Paula, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
por: Kivitz, Alan, et al.
Publicado: (2016)

Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome
por: Meythaler, Jay M., et al.
Publicado: (2021)

Nonmuscle myosin IIB is a driver of cellular reprogramming
por: Balaban, Amanda E., et al.
Publicado: (2023)

Large-scale genomic 2D visualization reveals extensive CG-AT skew correlation in bird genomes
por: Deng, Xuegong, et al.
Publicado: (2007)

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017)

Two-stage malignant transformation in hamster embryo cells
por: Poiley, J. A., et al.
Publicado: (1979)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Los filósofos modernos en la independencia latinoamericana
por: Cardiel Reyes, Raúl
Publicado: (1980)

Bajo el signo de jano /
por: Cardiel Reyes, Raúl
Publicado: (1968)

El próximo orden mundial /
por: Cardiel Reyes, Raúl
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_gqchj42m2k2cleunjuugj1b8m8